. 2022 Feb 22;39(4):1754–1771. doi: 10.1007/s12325-022-02060-1

Table 1.

Criteria used to identify a definite or probable NETs diagnosis

Definite NETs diagnosis	Probable NETs diagnosis
Had full insurance coverage for a long-term disease; or	Did not meet the diagnosis criteria for acromegaly or thyrotroph adenoma, and either had full healthcare coverage for a long-term disease or one hospitalization within 6 months of LA SSA treatment initiation linked to a metastatic cancer ICD-10 diagnosis code (Table S3); or
One cause of hospitalization linked to a NETs International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10) diagnosis code (Table S2)	Either underwent a medical liver procedure or had at least one hospitalization for liver metastasis within 6 months of LA SSA initiation, and had at least five blood or urinary tests of the same hormone, among tests likely to be performed during the follow-up of NETs (urine test for 5-hydroxindoleacetic acid, serum chromogranin A, serum gastrin, vasoactive intestinal peptide, serum insulin, free serum insulin; Table S4)

Definite NETs diagnosis

Probable NETs diagnosis

Had full insurance coverage for a long-term disease; or

Did not meet the diagnosis criteria for acromegaly or thyrotroph adenoma, and either had full healthcare coverage for a long-term disease or one hospitalization within 6 months of LA SSA treatment initiation linked to a metastatic cancer ICD-10 diagnosis code (Table S3); or

One cause of hospitalization linked to a NETs International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10) diagnosis code (Table S2)

Either underwent a medical liver procedure or had at least one hospitalization for liver metastasis within 6 months of LA SSA initiation, and had at least five blood or urinary tests of the same hormone, among tests likely to be performed during the follow-up of NETs (urine test for 5-hydroxindoleacetic acid, serum chromogranin A, serum gastrin, vasoactive intestinal peptide, serum insulin, free serum insulin; Table S4)